1729

Tolarex/Enlivex

Linial Michal, HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences

COVID-19

Enlivex:  Has developed a medication that could help treat severe symptoms of covid-19 including catastrophic organ failure.

Company Name

Enliex

Year Company was Founded

2005

About the Company

Enlivex Therapeutics R&D, a clinical-stage company focused on specialized cell immunotherapy, develops and commercializes an allogeneic drug pipeline for rebalancing immune hyper-responses.

The company’s Allocetra aims to effectively treat numerous acute conditions by using the body’s native mechanisms to restore rather than suppress immune balance. Enlivex aims to reshape the way immune, autoimmune, and inflammatory conditions are thought of and treated.

In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma, a stock market-listed clinical-stage company developing treatments for rare genetic diseases. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.

Links to Products

Allocetra™ is an innovative immunotherapy that is being developed to rebalance life-threatening hyperactivity of the immune system, using the immune system’s own natural regulation mechanisms. By intelligently engaging macrophages and dendritic cells, Allocetra™ is designed to avert cytokine storms and restores safe immune balance – without suppressing the immune system

Company Website

https://www.enlivex.com/

Video Links

https://www.youtube.com/channel/UCGJI8b2YMny7Gxu3mMrQlPg

Social Media Links

https://www.linkedin.com/company/enlivex-therapeutics-nasdaq-enlv/

https://twitter.com/EnlivexT

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
+972-2-6586692
Contact ME:
All projects by:Linial Michal (3)